Back to Search
DENNIS SARGENT, M.D.
M.D.
Surgery Physician
NPI: 1295823201IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery PhysicianPrimary
Surgery
Code: 208600000X
37173(CA)
Vascular Surgery Physician
Surgery — Vascular Surgery
Code: 2086S0129X
37173(CA)
Education
BOSTON UNIVERSITY SCHOOL OF MEDICINE
Class of 1977
Research & Publications (20)
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.
PMID 19124803·J Clin Oncol·2009
8-other
Current issues in oncology drug development, with a focus on Phase II trials.
PMID 19384696·J Biopharm Stat·2009
8-other
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
PMID 17876008·J Clin Oncol·2007
8-other
General and statistical hierarchy of appropriate biologic endpoints.
PMID 16773839·Oncology (Williston Park)·2006
8-other
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
PMID 16260700·J Clin Oncol·2005
4-observational
Comparison of artificial neural networks with other statistical approaches: results from medical data sets.
PMID 11309761·Cancer·2001
4-observational
Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial.
PMID 19564531·J Clin Oncol·2009
3-trial
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.
PMID 19577568·Gastroenterology·2009
8-other
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
PMID 19597023·J Clin Oncol·2009
8-other
Clinical trial designs for predictive biomarker validation: one size does not fit all.
PMID 19384694·J Biopharm Stat·2009
8-other
Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
PMID 19622902·Oncology·2009
3-trial
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.
PMID 19470929·J Clin Oncol·2009
4-observational
Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.
PMID 19414682·J Clin Oncol·2009
8-other
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144.
PMID 19423501·Clin Colorectal Cancer·2009
8-other
Clinical implications of microsatellite instability in sporadic colon cancers.
PMID 19444104·Curr Opin Oncol·2009
6-review
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.
PMID 19390940·Int J Clin Oncol·2009
6-review
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.
PMID 19636001·J Clin Oncol·2009
4-observational
Importance of randomization in early clinical trials.
PMID 19521327·Clin Adv Hematol Oncol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12462 PUTNAM ST, SUITE 200
WHITTIER, CA 90602 - Phone
- (562) 789-5489
Quick Facts
- NPI
- 1295823201
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 49
- Publications
- 20
Are you this provider?
Claim Your Profile